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ABSTRACT
Background: Interindividual variation in the response to diet is
common, but the underlying mechanism for such variation is
unclear.
Objective: The objective of this study was to use a metabolic pro-
iling approach to identify a panel of urinary metabolites represent-
ing individuals demonstrating typical (homogeneous) metabolic re-
sponses to healthy diets, and subsequently to deine the association
of these metabolites with improvement of risk factors for cardiovas-
cular diseases (CVDs).
Design: 24-h urine samples from 158 participants with pre-
hypertension and stage 1 hypertension, collected at baseline and fol-
lowing the consumption of a carbohydrate-rich, a protein-rich, and a
monounsaturated fat–rich healthy diet (6 wk/diet) in a randomized,
crossover study, were analyzed by proton (1H) nuclear magnetic res-
onance (NMR) spectroscopy. Urinary metabolite proiles were inter-
rogated to identify typical and variable responses to each diet. We
quantiied the differences in absolute excretion of metabolites, dis-
tinguishing between dietary comparisons within the typical response
groups, and established their associations with CVD risk factors us-
ing linear regression.
Results:Globally all 3 diets induced a similar pattern of change in the
urinary metabolic proiles for the majority of participants (60.1%).
Diet-dependent metabolic variation was not signiicantly associated
with total cholesterol or low-density lipoprotein (LDL) cholesterol
concentration. However, blood pressure (BP) was found to be sig-
niicantly associated with 6 urinary metabolites relecting dietary
intake [proline-betaine (inverse), carnitine (direct)], gut microbial
co-metabolites [hippurate (direct), 4-cresyl sulfate (inverse), pheny-
lacetylglutamine (inverse)], and tryptophan metabolism [N-methyl-
2-pyridone-5-carboxamide (inverse)]. A dampened clinical response
was observed in some individuals with variable metabolic responses,
which could be attributed to nonadherence to diet (≤25.3%), vari-
ation in gut microbiome activity (7.6%), or a combination of both
(7.0%).
Conclusions: These data indicate interindividual variations in BP in
response to dietary change and highlight the potential inluence of
the gut microbiome in mediating this relation. This approach pro-
vides a framework for stratiication of individuals undergoing di-
etary management. The original OmniHeart intervention study and
the metabolomics study were registered at www.clinicaltrials.gov as
NCT00051350 and NCT03369535, respectively. Am J Clin Nutr
2018;107:323–334.
Keywords: diets, gut microbiome, hypertension, metabolic proil-
ing, metabonomic, metabolomic, personalized health care
INTRODUCTION
Of total global deaths, approximately half are attributed to car-
diovascular diseases (CVDs), with elevated blood pressure (BP)
being a key risk factor (1). Genome-wide association studies have
identiied common genetic variants associated with high BP (2)
but these only account for a small proportion of the population
variance in BP and do not take lifestyle factors such as physical
inactivity or unhealthy diet into account. CVD remains the lead-
ing cause of mortality for noncommunicable diseases worldwide,
even though the adoption of healthy dietary patterns such as those
promoted by Dietary Approaches to Stop Hypertension (DASH)
(3), Optimal Macronutrient Intake Trial for Heart Health (Om-
niHeart) (4), and Mediterranean diets (5) has unequivocally been
shown to reduce CVD risk. Humans demonstrate substantial vari-
ation in response to dietary intervention, partially attributable to
genetic heterogeneity (6, 7). For example, the apolipoprotein A-
IV protein modulates cholesterol-lowering responses to high-fat
diets (8, 9). However, supporting evidence for genetic inluence
on variable dietary responses remains conlicting (10) andmodii-
able factors such as changes in body weight (11, 12), or variation
in the composition of the gut microbiome (13) and virome (14),
have been implicated in variation in dietary responses.
Am J Clin Nutr 2018;107:323–334. Printed in USA. © 2018 American Society for Nutrition. This is an Open Access article distributed under the terms of the
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Metabolic phenotyping technologies provide a framework for
investigating the inluences of environmental and lifestyle fac-
tors on disease risk and have been successfully applied to in-
vestigate chronic diseases, e.g., diabetes (15). Systematic mod-
ulation of metabolism in response to food intake (16) has been
reported and the impact of diet on a range of pathological con-
ditions, including gastrointestinal cancer risk, has been assessed
(17). Building on methodological approaches developed for char-
acterizing interindividual variation in response to drug toxicity or
therapies (18), we propose to demonstrate the feasibility of iden-
tifying interindividual variation in clinical response to 3 different
healthy diets, using a 1H nuclear magnetic resonance (NMR)-
based metabolic phenotyping approach, and establish the im-
pact of this variation on CVD risk. We hypothesized that dietary
change from a typical American diet to a healthy diet or between
different healthy diets would result in typical changes in the uri-
nary metabolic phenotypes for the majority of individuals, herein
considered as the homogeneous dietary response (HDR) group.
We ascertained that a minority of individuals demonstrated atyp-
ical dietary responses, herein referred to as the variable (het-
erogeneous or nonuniform) dietary response (VDR) group. We
further hypothesized that these speciic urinary dietary response
phenotypes would be associated with BP. Variation in diet-
speciic biomarkers will further enhance our understanding of the




TheOmniHeart study (N= 163)was a randomized, controlled,
3-period cross-over feeding study aiming to assess the effects of
3 healthy diets on BP and lipid proiles (19). The key indings
and study design of the OmniHeart study have been previously
published (4, 19). Briely, all 3 OmniHeart diets had a similar nu-
trient composition to the established healthy DASH diet but var-
ied in macronutrient composition. The Omniheart carbohydrate-
rich diet (OmniCarb diet) provided 58% kcal from carbohydrate,
15% from protein, and 27% from fat; the remaining 2 diets
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replaced 10% of calories from carbohydrate with either protein,
predominantly obtained from vegetable sources (OmniProt diet),
or unsaturated fats, predominantly derived from monounsatu-
rated fat (OmniMFA diet). Participants were randomly assigned
to 1 of 6 possible orders of administration of the 3 diets, each
intervention period lasting for 6 wk. During each intervention
period, the participants were requested to only consume food
prepared in the diet kitchen and were allowed to consume ≤2 al-
coholic beverages/d and 3 noncaloric caffeinated beverages/d as
part of the trial. Their main meal was consumed on-site on week-
days and all other meals were eaten at home. Participants com-
pleted a diary in which they indicated whether they had complied
with the study food protocol during the feeding periods. During
the screening visits and washout periods (≥2 wk), participants
consumed their own food. The Willett food frequency question-
naire (20), administered by certiied staff as a means to describe
the usual food intake of participants during screening visits, indi-
cated participants consumed a typical American diet at the outset
of the study, corresponding to high intake of saturated fat, exces-
sive reined sugar, and salt with low intake of fruit, vegetables,
and omega-3-fat.
A total of 163 men and women aged 30–80 y from the Bal-
timore and Boston areas, with prehypertension (systolic BP of
120–139 mmHg and/or diastolic BP of 80–89 mmHg) or stage
1 hypertension (systolic BP of 140–159 mm Hg and/or diastolic
BP of 90–99 mm Hg) and without diabetes or prior CVD, were
recruited to the study. Theminimum detectable, between-diet dif-
ferences for primary (systolic BP) and secondary (diastolic BP,
LDL cholesterol, HDL cholesterol, triglyceride, and total choles-
terol) variables in the full cohort (n = 160) and in subgroups
(n = 80 and 70) were at 80% and 90% power (2-sided alpha,
P = 0.05).
The sample size of the trial (n = 160) was selected because
it provided adequate power to detect between-diet differences in
the primary outcome variables that have public health signii-
cance, both overall and in subgroups. Speciically, the minimum
detectable effect size for systolic BP was<3 mmHg even in sub-
groups that comprised only 40% (n = 64) of participants. One
individual completed just 1 dietary intervention period, and 4 in-
dividuals completed 2 intervention periods. The remaining 158
completed all 3 dietary interventions, provided four 24-h urine
collections, and supplied anthropometric and sociodemographic
metrics on CVD (Supplemental Figure 1). These four 24-h urine
collections corresponded to the baseline screening visit and 1 at
the end of each of the three 6-wk dietary interventions. NMR
urine spectra for these 158 individuals were used for the analyses
presented here. During the last 10 d of each dietary intervention
period, a fasting blood specimen was obtained to measure lipid
concentrations. BP was measured on 5 d by trained staff using
the OMRON 907 device for those requiring a normal or large
adult cuff, after participants had been seated for ≥5 min. The re-
ported BP was based on the average of 9 BP measurements taken
at screening visits and 15 measurements taken at the last 5 visits
of each feeding period. Bodyweight for all participants wasmain-
tained within 2% of their baseline throughout the study period
by adjusting caloric levels each weekday. Baseline sociodem-
ographic and anthropometric characteristics were obtained for
each participant. Institutional ethics committee approval was ob-
tained for each site and all participants provided written informed
consent.
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NMR-based metabolic phenotyping and data processing
Urine specimens were analyzed by 600 MHz 1H NMR spec-
troscopy using a Bruker NMR spectrometer (Bruker Biospin,
Rheinstetten, Germany) according to a standard protocol (21) in
our London metabolic phenotyping laboratory. Urine specimens
were allowed to thaw at room temperature and centrifuged at
12,000 g for 5 min to remove particulates. For each specimen,
500 µL of urine was mixed with 250 µL of phosphate buffer so-
lution at pH 7.4 ± 0.1. The resulting mixtures were left to stand
for 10 min and then further centrifuged as before. A total volume
of 500 µL of the supernatant was added to 50 µL of sodium
3-trimethylsilyl-(2,2,3,3-2H4)-1-propionate (TSP) in deuterium
oxide, giving a inal concentration of 1 mM. This solution was
transferred to a 5-mm NMR tube. The prepared urine specimens
were placed in the auto-sampler and analyzed in a simple random-
ized order generated by computer. A 1-dimensional (1D) pulse
sequence with a water saturation method (recycle delay–90°–t1–
90°–tm–90°–acquisition) was used to acquire standard
1H NMR
spectra of the urine. The spectra were acquired with 64K data
points and 128 scans over a spectral width of 12 kHz. The re-
cycle delay was set to 2 s with a mixing time (tm) of 100 ms
and a t1 of 20 µs, providing an acquisition time of approximately
2.72 s. All 1H NMR spectra were phased, baseline corrected, and
manually referenced to TSP at δ 0 with Topspin software (ver-
sion 2.1, Bruker Biospin) prior to multiplication by an exponen-
tial weighting function corresponding to a line broadening of 0.3
Hz. The spectral regions containing the water (δ 4.5–5.05) and
urea (δ 5.5–6.5) resonances, as well as the extreme ends (<δ 0.7
and >δ 9.5) of the spectra that contain minimal metabolic in-
formation, were removed. Initial analysis showed that the signal
arising from the –CH2 and –CH3 group of the creatinine peaks
dominated the analysis due to the high concentration of creatinine
compared to other metabolites. Since there was no statistical dif-
ference in the clinical creatinine measurements at screening visit
and at the end of each study period based on Jaffé reaction mea-
surement (P> 0.5 for all comparisons between each diet and the
baseline), we removed the creatinine regions containing the peaks
at δ 3.035–3.062 and δ 4.052–4.075 from all subsequent analy-
sis. A total of 23,998 NMR data variables, at a full resolution
(0.0003 ppm), were then normalized by a probabilistic quotient
method (22) using the median spectrum of the whole data-set as
a reference and subsequently scaled to unit-variance.
Data analysis
We applied Statistical HOmogeneous Cluster SpectroscopY
(SHOCSY) (23) to the processed and normalized spectroscopic
data. SHOCSY is a variant of statistical spectroscopic techniques
such as Subset Optimization by Reference Matching (STORM)
(24) and Statistical TOtal Correlation SpectroscopY (STOCSY)
(25). SHOCSY involves clustering of the spectral data based on
the similarity or dissimilarity of the spectral features followed
by the association of clusters to different dietary groups using
an enrichment test. The application of SHOCSY enables iden-
tiication of the groups of spectra showing uniform or ho-
mogeneous urinary metabolic responses (HDR) and those
showing variation from the coherent metabolic response (VDR)
following the consumption of different OmniHeart diets. Due
to the nature of the cross-over study design, we employed
multilevel orthogonal partial least squares discriminant analysis
(mOPLSDA) (26, 27), which incorporates the variation between
and within participants in the data-set to optimize visualiza-
tion of dietary response, in conjunction with SHOCSY. We per-
formed this in a pairwise fashion, comparing the urinary spec-
tral data from the screening visit (relecting a basal dietary
pattern) with those from the end of each dietary intervention,
and modelled this separately for the urinary spectral data corre-
sponding to an HDR (3 models, 1 model/diet) and those repre-
senting a VDR (3 models). Thus, each subgroup was compared
to its own baseline. We also performed comparison between dif-
ferent OmniHeart diets and separately for the HDR (3 models)
and VDR (3 models) groups, creating a total of 12 different
mOPLSDA models (Supplemental Table 1). Each mOPLSDA
comparison was validated using a 7-fold cross-validation proce-
dure. The model statistics, Q2Yhât (28), is deined as the propor-
tion of variance in the data predicted by the mOPLSDA model
and is therefore a measure of the robustness of the model. In ad-
dition, permutation testing was performed by randomly assigning
classes to the samples and remodeling repeatedly 100 times. The
Q2Yhât statistic for the real model was then compared to the null
hypothesis distribution obtained from the permuted Q2Yhât t val-
ues and was considered signiicant when the P value of the real
Q2Yhât was <0.05 on those permuted values.
The 3 criteria used to identify discriminatorymetabolites were:
(i) P values of the correlations between the spectral variable and
the mOPLSDA scores vector should be <1.85 × 10−6 (corre-
sponding to P< 0.05 after Sidák correction); (ii) a variable load-
ing coeficient strength, r2 > 0.3 as deined in Zou et al. (23); and
(iii) the stability of the NMR variables, whereby a data point was
considered signiicant when lanked by 2 NMR spectral variables
conforming to criteria (i) and (ii). For peaks that were free from
spectral overlap, the 24-h urinary excretion of each discrimina-
tory metabolite was quantiied by integration of the NMR signal
intensities. Since we found no signiicant difference in the ex-
cretion of creatinine between different OmniHeart diets and the
typical American diet (P > 0.5), the absolute excretion of each
discriminatory metabolite was normalized to the corresponding
24-h urinary creatinine excretion (in mmol/L). The difference in
absolute excretion of each discriminatory metabolite was deter-
mined for the comparison of each dietary intervention with base-
line or between different OmniHeart dietary interventions. The
association between the differences in absolute excretion of each
discriminatory metabolite and changes in CVD risk factors (sys-
tolic and diastolic BP, LDL, total cholesterol) was established
using linear regression for HDR groups. In addition, known co-
variates for hypertension, including urinary excretion of sodium,
potassium, calcium, and phosphate, were also established for the
HDR and VDR groups for the comparisons between baseline and
each OmniHeart diet. The statistical signiicance of these covari-
ates was adjusted by Bonferroni correction (0.05 divided by num-
ber of comparisons) to account for multiple testing. All analyses
were performed using in-house software written in Matlab (ver-
sion 2012a, MathWorks, Natick, MA).
Identiication of discriminatory metabolites
The discriminatory metabolites found to be signiicantly
inluenced by the healthy dietary interventions were con-
irmed by in-house and published database (29) references and
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authenticated by spiking in standard compounds purchased
from Sigma Aldrich. These compounds included: N-methyl-
2-pyridone-5-carboxamide, 4-hydroxyphenylacetic acid, carni-
tine, creatine, dimethylglycine, S-methyl-L-cysteine-S-oxide,
N-methyl nicotinic acid,N-methyl nicotinamide, proline-betaine,
and hippurate. For the remaining urinary metabolites where they
were not available commercially, identiication was achieved us-
ing further analytical methods such as 2-dimensional NMR ex-
periments, solid phase extraction chromatography experiments
coupled with NMR, ultra-performance liquid chromatography
coupled to mass spectroscopy, and statistical analysis such as
STORM (24) as well as using published databases and/or liter-
ature.
RESULTS
Individuals show variation in urinary metabolic phenotypes
on OmniHeart diets
Participants’ demographics and changes in CVD risk fac-
tors following each OmniHeart diet are provided in Table 1.
Each diet elicited a range of clinical responses over the 6-wk
study in terms of reduction of CVD risk factors, which was re-
lected in the urinary metabolome. Interindividual differences
in dietary response were observed; the majority of the partici-
pants showed a HDR to all of the OmniHeart diets when com-
pared to the baseline proile: 71.5% (n = 113) for OmniProt,
80.4% (n = 127) for OmniMFA, and 86.7% (n = 137) for Om-
niCarb. The remaining individuals who did not demonstrate a
“typical” response to a given diet were grouped into the VDR
class: n = 45 for OmniProt, n = 31 for OmnMFA, and n = 21
for OmniCarb. A similar modeling strategy was applied to com-
pare between pairs of OmniHeart diets. We found >70% par-
ticipants showed consistent metabolic differences between diets
(Supplemental Table 1).
OmniHeart diets show distinctive urinary metabolic
phenotypes
Each of the 3 OmniHeart diets was associated with a dis-
tinct metabolic phenotype in the majority of participants (the
HDR group). For the OmniHeart–baseline comparisons, the
discriminatory metabolites were predominantly related to:
(i) dietary intake—increased excretion of proline-betaine,
N-acetyl-S-methyl-L-cysteine sulfoxide, S-methyl-L-cysteine-
S-oxide, creatine, and carnitine; (ii) tryptophan–NAD
degradation—reduced excretion of N-methyl-2-pyridone-
5-carboxamide and N-methyl nicotinamide, and increased
excretion of N-methyl nicotinic acid; and (iii) gut mi-
crobial mammalian metabolism—increased excretion of
hippurate and dimethylglycine, and reduced excretion of
4-hydroxyphenylacetic acid (Supplemental Table 2). Compared
to the baseline proiles, proline-betaine was the only metabolite
uniformly increased in the urinary phenotypes of HDR groups
across all 3 diets, consistent with increased citrus fruit consump-
tion (30). Increased excretion of carnitine and creatine in the
OmniProt diet relected the increase in protein intake (31).
Additional pairwise comparisons (P < 10−5) between differ-
ent OmniHeart diets further indicated that each diet was associ-
ated with a distinct metabolic phenotype. The HDR group of the
OmniProt diet was generally characterized by higher excretion of
urinary creatine, N-methyl-2-pyridone-5-carboxamide and 2 gut
microbial mammalian co-metabolites, phenylacetylglutamine,
and 4-cresyl sulfate compared to the other 2 OmniHeart diets;
whilst the HDR group for the OmniCarb diet consistently showed
higher excretion of hippurate and guanodinoacetate (Supple-
mental Tables 3 and 4). The differences in themarkers for dietary
intake of cruciferous vegetables (S-methyl-L-cysteine-S-oxide
and N-acetyl-S-methyl-L-cysteine sulfoxide) (32) and markers
for citrus fruit intake (proline-betaine) (30) observed when com-
paring urine of OmniHeart diets with the baseline proiles, were
generally not observed for pairwise comparisons between the
OmniHeart diets since all 3 diets included higher proportions of
fruits or vegetables than the baseline.
Urinary metabolites signiicantly associated with BP
We quantiied 10 discriminatory metabolites altered in
response to 1 or more OmniHeart diets and assessed their
associations with BP and lipid proiles using the HDR groups
only. Although no signiicant associations were found between
dietary phenotypes and LDL or total cholesterol, we found
signiicant associations between 2 of these food-related metabo-
lites and BP. Proline-betaine was inversely associated with
systolic and diastolic BP for OmniCarb and OmniMFA diets
when compared to baseline (P < 0.05, Table 2). A similar
trend was observed for the OmniProt diet although it was not
statistically signiicant. A direct association was found be-
tween systolic BP and carnitine for the OmniProt diet when
compared to baseline (P < 0.05). We found 3 metabolites
related to host-gut microbial pathways that were signiicantly
associated with BP (hippurate, phenylacetylglutamine, and
4-cresyl sulfate). Hippurate showed a direct association with
systolic BP (P < 0.001) and diastolic BP (P < 0.01) levels
for the OmniCarb diet compared to baseline, whereas 4-cresyl
sulfate and phenylacetylglutamine (distal colonic microbial
metabolites of tyrosine and phenylalanine, respectively) were
inversely associated with BP for the comparison between
OmniMFA and OmniProt diets. N-methyl-2-pyridone-5-
carboxamide (tryptophan–NAD metabolite) was also found
to be inversely associated with systolic and diastolic BP levels
for the OmniCarb–baseline comparison (P < 0.05). These data
demonstrate healthy diets can elicit coherent changes in the
urinary metabolic phenotypes for the majority of individuals and
that some of these metabolites are either directly or inversely
associated with BP.
Urinary metabolic phenotypes can identify nonadherence to
diets
The urinary spectral data for the VDR groups for each of
the OmniHeart diets typically produced fewer dietary-speciic
discriminatory metabolites than the HDR groups (Supplemental
Tables 2 and 3). The VDR groups also showed discordance in
the concentrations of proline-betaine and hippurate when com-
pared to the HDR groups. Since increased consumption of
citrus fruits was a feature of all dietary interventions, we there-
fore classiied individuals with a lower concentration of proline-
betaine (a direct marker of citrus fruit intake) (33, 34) as non-
adherent to these diets on the assumption that this was gener-
ally indicative of dietary behavior. We found the majority of
participants in the VDR groups excreted lower 24-h urinary
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TABLE 1
Characteristics of participants who completed all 3 OmniHeart diets (n = 158)1
Characteristics P values
Age, mean ± SD 53.1 ± 10.8
Ethnicity, n (%)
African American 86 (54.4)







Obesity status, n (%)








No alcohol, n (%) 88 (56)
Serving per week among drinkers, mean ± SD 4.17 ± 3.5
Education, n (%)
≤ High school 32 (20.3)
Some college 53 (33.5)
College graduate 73 (46.2)
Mean changes in SBP from baseline (95% CI), mm Hg
OmniCarb diet –8.0 (–9.4, –6.6) ‡
OmniMFA diet –9.4 (–10.7, –8.1) ‡
OmniProt diet –9.4 (–10.8, –8.1) ‡
Mean changes in DBP from baseline (95% CI), mm Hg
OmniCarb diet –4.1 (–4.9, –3.3) ‡
OmniMFA diet –4.9 (–5.7, –4.1) ‡
OmniProt diet –5.3 (–6.1, –4.4) ‡
Mean changes in LDL cholesterol from baseline (95% CI), mg/dL
OmniCarb diet –11.6 (–14.6, –8.6) ‡
OmniMFA diet –13.2 (–16.5, –9.9) ‡
OmniProt diet –14.4 (–17.7, –11.1) ‡
Mean changes in HDL cholesterol from baseline (95% CI), mg/dL
OmniCarb diet –1.5 (–2.6, –0.3) *
OmniMFA diet –0.4 (–1.4, 0.6)
OmniProt diet –2.7 (–3.7, –1.7) †
Mean changes in triglyceride from baseline (95% CI), mg/dL
OmniCarb diet –0.2 (–9.1, 8.7)
OmniMFA diet –9.7 (–17.9, –1.5) *
OmniProt diet –16.5 (–25.8, –7.3) *
Mean changes in total cholesterol from baseline (95% CI), mg/dL
OmniCarb diet –12.5 (–15.8, –9.1) ‡
OmniMFA diet –15.6 (–19.2, –11.9) ‡
OmniProt diet –20.2 (–23.7, –16.7) ‡
1T test comparison between baseline clinical data and after each dietary intervention: *P< 0.05; †P< 10−5;
‡P < 10−10. DBP, diastolic blood pressure; OmniCarb, OmniHeart carbohydrate-rich diet; OmniHeart, Optimal
Macronutrient Intake Trial for Heart Health; OmniMFA, OmniHeart monounsaturated fat-rich diet; OmniProt,
OmniHeart protein-rich diet; SBP, systolic blood pressure.
concentrations of proline-betaine when compared to the HDR
groups. Fifteen of the 21 individuals (71.4%) from the
OmniCarb-VDR group showed a 24-h urinary excretion of less
than the lower 95% CI obtained for proline-betaine excretion
of the OmniCarb-HDR group. A similar trend was observed for
the OmniMFA-VDR (21/31, 67.7%) and OmniProt-VDR (35/45,
77.8%) groups. The overall estimation of nonadherence to each
diet was: 9.5% (n = 15) for the OmniCarb, 13.3% (n = 21) for
the OmniMFA, and 22.2% (n = 35) for the OmniProt diet. De-
spite sub-classiication of VDR groups as adherent or nonadher-
ent, contrasting patterns remained in the VDR and HDR groups,
as exempliied for hippurate (a gut microbial co-metabolite of di-
etary phenols), where increased excretion of hippurate was char-
acteristic for the HDR but not either of the VDR (diet adherent or
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TABLE 2
Estimated mean differences in CVD risk factors1
2 SD excretion Total cholesterol
Urinary metabolites (mmol/L) SBP (mm Hg) DBP (mm Hg) LDL-C (mg/dL) (mg/dL)
Homogeneous dietary responders for OmniCarb diet vs. baseline (n = 137)
Proline-betaine 1.25 –4.10 (–2.90) † –1.77 (–2.15)* –3.90 (–1.26) –3.94 (–1.17)
Hippurate 3.47 6.14 (4.64) ‡ 2.27 (2.79) † –1.47 (–0.48) 2.70 (0.80)
N-methyl-2-pyridone-5-carboxamide 0.21 –3.03 (–2.24)* –1.77 (–2.19)* 2.22 (0.75) 3.49 (1.11)
N-methyl nicotinic acid 0.27 –0.20 (–0.14) 0.59 (0.71) –1.94 (0.64) –0.25 (–0.07)
N-methyl nicotinamide 0.03 –0.86 (–0.60) –0.75 (–0.97) 0.60 (0.20) –0.55 (0.17)
Homogeneous dietary responders for OmniMFA vs. baseline (n = 127)
Proline-betaine 0.87 –3.53 (–2.76) † –1.73 (–2.20)* 2.41 (0.73) 1.87 (0.48)
Homogeneous dietary responders for OmniProt vs. baseline (n = 113)
Proline-betaine 0.74 –1.16 (0.74) 0.14 (0.16) 1.31 (0.33) –1.42 (–0.33)
Carnitine 0.29 3.11 (1.99)* 1.13 (1.38) 0.45 (0.11) 1.03 (0.24)
Creatine 1.62 1.54 (1.05) –1.19 (–0.24) –4.34 (–1.11) –6.87 (–1.65)
Homogeneous dietary responders for OmniCarb vs. OmniMFA (n = 113)
Guanodinoacetate 0.95 0.29 (0.35) 0.06 (0.09) –0.51 (–0.21) 2.70 (0.94)
Homogeneous dietary responders for OmniCarb vs. OmniProt (n = 134)
Phenylacetylglutamine 0.70 –0.89 (–0.96) –0.93 (–1.42) –2.82 (–1.18) –0.44 (–0.15)
4-cresyl sulfate 0.27 0.06 (0.07) 0.73 (1.11) –0.91 (–0.79) 1.02 (0.35)
Homogeneous dietary responders for OmniMFA vs. OmniProt (n = 118)
Phenylacetylglutamine 0.68 –1.7 (–1.93) –1.89 (–3.32) † 0.31 (0.13) –0.33 (–0.14)
4-cresyl sulfate 0.30 –2.68 (–3.05) † –2.15 (–3.74) † 0.73 (0.31) –0.27 (–0.11)
1The SBP, DBP, LDL-C, and total cholesterol mean differences per 2-SD increase in absolute excretion for the comparison between baseline and post-
OmniHeart diets and between different OmniHeart diets for the HDR groups. The correlations between changes in metabolites and CVD factors were evaluated
by linear regression. 2 SD excretion of each urinary metabolite was calculated by the absolute differences between dietary comparisons. Numbers in parenthesis
are z scores, i.e., regression coeficient divided by standard error (z score ≥ 1.96, P < 0.05; ≥2.58, P < 0.01; ≥3.89, P < 0.001). NMR chemical shifts (mul-
tiplicity) used for quantiication: proline-betaine, δ3.11 (singlet); hippurate, δ7.64 (triplet); N-methyl-2-pyridone-5-carboxamide, δ6.67 (doublet); N-methyl
nicotinic acid, δ4.44 (singlet); N-methyl nicotinamide, δ8.89 (triplet); carnitine, δ3.23 (singlet); creatine, δ3.93 (singlet); guanodinoacetate, δ3.80 (singlet);
phenylacetylglutamine, δ7.43 (triplet); 4-cresyl sulfate, δ2.35 (singlet). CVD, cardiovascular disease; DBP, diastolic blood pressure; LDL-C, LDL choles-
terol; NMR, nuclear magnetic resonance; OmniCarb, OmniHeart carbohydrate-rich diet; OmniHeart, Optimal Macronutrient Intake Trial for Heart Health;
OmniMFA, OmniHeart monounsaturated fat–rich diet; OmniProt, OmniHeart protein-rich diet; SBP, systolic blood pressure.
*P < 0.05; †P < 0.01; ‡P < 0.001.
nonadherent) subgroups for OmniCarb. Differential metabolite
patterns were also observed for different subgroups within the
OmniMFA (Figure 1).
Urinary metabolic variation relects interindividual
differences in clinical responses
Discarding the nonadherent VDR group, we assessed the ef-
fect of each diet, stratiied by HDR group compared to adherent-
VDR group, on urinary electrolyte concentrations. We found sig-
niicant overall changes in mean urinary sodium (decrease) and
mean urinary potassium (increase) in the HDR groups for all Om-
niHeart diets when compared to baseline values (Supplemen-
tal Table 5). The mean changes in urinary electrolytes were of
slightly greater magnitude when considering the subset of pre-
hypertensive individuals within the HDR groups for sodium:
–31.3 mmol/d (OmniCarb), –44.9 mmol/d (OmniMFA), and
–35.9 mmol/d (OmniProt); and potassium 26.4 mmol/d (Omni-
Carb), 28.4 mmol/d (OmniMFA), and 24.7 mmol/d (OmniProt),
P < 0.001 (data not shown). This general trend in mean urinary
sodium and potassium levels was apparent for the adherent-VDR
groups but the changes from baseline level were insigniicant.
With regard to the intercomparison between OmnniHeart diets,
no systematic differences were observed in the electrolyte levels
with the exception of higher urinary sodium and phosphate lev-
els being characteristic of the OmniProt-HDR when compared to
the OmniMFA-HDR group (P < 0.01, data not shown). No sys-
tematic differences in electrolytes were expected as micronutri-
ents such as potassium, sodium, calcium, and magnesium were
indexed to the energy level from the diet for each participant
(19).
We also investigated the changes in CVD risk factors post-
diet and found a signiicant (P < 10−10) reduction in all HDR
diet groups when compared to the baseline for systolic and di-
astolic BP, LDL cholesterol, and total cholesterol. Addition-
ally, the reduction in serum triglyceride concentrations was sig-
niicant for the OmniProt-HDR group; and HDL cholesterol
for the OmniCarb-HDR and OmniProt-HDR groups, P < 0.05
(Figure 2). High-risk individuals such as those who were hy-
pertensive or those with nonoptimal lipid proiles in the HDR
groups showed greater reduction in these CVD risk factors
than low-risk individuals (Supplemental Figure 2). For all
the VDR groups, a dampened reduction in CVD risk fac-
tors was generally observed when compared to the corre-
sponding HDR comparator groups (Figure 2). A signiicant
(P < 0.05) reduction in systolic and diastolic BP was observed
in both the adherent- and nonadherent-OmniMFA-VDR and the
non-adherent-OmniProt-VDR groups; whilst the adherent- and
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FIGURE 1 The observed mean differences in excretion for hippurate between HDR and adherent- and nonadherent-VDR groups when OmniHeart diets
and their corresponding baseline spectra were compared. Open square, OmniCarb-HDR (n= 137); light-grey closed square, adherent-OmniCarb-VDR (n= 6);
dark-grey closed square, nonadherent-OmniCarb-VDR (n = 15); open circle, OmniMFA-HDR (n = 127); light-grey closed circle, adherent-OmniMFA-VDR
(n = 10); dark-grey closed circle, nonadherent-OmniMFA-VDR (n = 21); open triangle, OmniProt-HDR (n = 113); light-grey closed triangle, adherent-
OmniProt-VDR (n= 10); dark-grey closed triangle, nonadherent-OmniProt-VDR (n= 35). Error bars indicate 95% CIs. Signiicant t test comparison between
baseline and post OmniHeart diets: *P < 0.05; ‡P < 10−10. HDR, homogeneous dietary response; OmniCarb, OmniHeart carbohydrate-rich diet; OmniHeart,
Optimal Macronutrient Intake Trial for Heart Health; OmniMFA, OmniHeart monounsaturated fat–rich diet; OmniProt, OmniHeart protein-rich diet; VDR,
variable dietary response.
non-adherent-OmniProt-VDR groups also generally showed sig-
niicant reductions for LDL, HDL, and total cholesterol al-
though the magnitude of the change in CVD risk factors
was generally more variable than that observed for the corre-
sponding HDR groups. The observed lack of dietary-induced
clinical beneit in the adherent-VDR groups may be partially
due to the reduced sample size (n < 10) following stratiica-
tion of the cohort. In addition to the observation that HDR
groups of all 3 OmniHeart diets generally elicited a reduc-
tion in CVD risk factors when compared to typical Ameri-
can diets, we also found the HDR-OmniProt group generally
showed a larger overall reduction in CVD risk factors when
compared to the HDR-OmniMFA and HDR-OmniCarb groups
(Supplemental Figure 3).
Stratiication of individual response based on urinary
metabolic phenotypes
From a cohort of 158 individuals, who partook in all 3 dietary
interventions, we were able to stratify individuals according to
diet-response speciic urinary phenotypes: corresponding to those
who demonstrated: HDR to all 3 diets (n= 95, 60.1%; Group 1);
HDR to 2 diets but VDR to 1 diet (n = 35, 22.2%; Group 2);
HDR to only 1 diet but VDR to 2 diets (n= 22, 13.9%; Group 3);
non-adherent-VDR to all 3 diets (n= 4, 2.5%; Group 4); and mix
of nonadherent- and adherent-VDR to all 3 diets (n = 2, 1.3%;
Group 5). Moreover, we were able to further sub-stratify indi-
viduals in the VDR groups that demonstrated a dampened clin-
ical response into those participants that were: (a) adherent to
diets but showed differences in metabolic phenotypes from the
majority of participants (including gut-microbial co-metabolites;
n = 12, 7.6%); (b) nonadherent to ≥1 diet (n = 40, 25.3%);
or (c) a combination of the 2 (n = 11, 7.0%); see Table 3. We
found that individuals consistently classiied as HDR for all 3
OmniHeart diets generallymanifested a greater reduction in CVD
risk factors than those that were classiied as HDR for just 1 or 2
of the OmniHeart diets (Supplemental Figure 4).
DISCUSSION
We show that the majority, but not all, of the participants re-
sponded similarly in terms of their expressed metabolic pheno-
type to a particular diet and that each of the 3 diets had a distinct
effect on the metabolism. However, regardless of the macronu-
trient differences between the 3 OmniHeart diets and the diet-
speciic impact on the metabolic proile, the majority of partic-
ipants (60.1%), demonstrated post-diet improvement in clinical
risk factors for CVD. We applied an agnostic multivariate sta-
tistical tool to identify participants who showed a coherent bio-
chemical response (HDR) to each of the diets and subdivided the
data-set into high- and low-risk individuals based on their BP sta-
tus or lipid proiles. Although both groups demonstrated a co-
herent biochemical response irrespective of the CVD risk status,
the high-risk groups generally demonstrated a larger reduction
in CVD risk factors than low-risk individuals. Our results thus
demonstrate that manipulation of dietary macronutrient content,
without alteration of caloric intake and bodyweight, can elicit co-
herent changes in metabolic proiles and contribute to beneicial
effects on both BP levels and lipid proiles.
Notably, we identiied 2 gut microbial-host co-metabolites as-
sociated with BP: phenylacetylglutamine and 4-cresyl sulfate, de-
riving from phenylalanine and tyrosine, respectively, resulting
from bacterial putrefaction of protein in the distal colon. The gut
microbiota, in particular Firmicutes and Bacteroidetes, can adapt
to dietary changes and induce changes in host metabolism (35):
an increase of Firmicutes-to-Bacteroidetes ratio has been demon-
strated in spontaneous hypertensive rats (36). Other researchers
Downloaded from https://academic.oup.com/ajcn/article-abstract/107/3/323/4915937
by University of Kent user
on 12 April 2018


















































































































































































































































































OmniCarb OmniMFA OmniProt OmniCarb OmniMFA OmniProt
OmniCarb OmniMFA OmniProt OmniCarb OmniMFA OmniProt
OmniCarb OmniMFA OmniProt OmniCarb OmniMFA OmniProt
HDR Adherent-VDR Nonadherent-VDR
FIGURE 2 Key observations for changes in the cardiovascular disease risk factors showing differences in HDR and VDR groups for the comparisons
between each OmniHeart diet and baseline corresponding to the changes in systolic BP (A), diastolic BP (B), LDL cholesterol (C), HDL cholesterol (D),
triglycerides (E), and total cholesterol (F). Open square, OmniCarb-HDR (n = 137); light-grey closed square, adherent-OmniCarb-VDR (n = 6); dark-grey
closed square, nonadherent-OmniCarb-VDR (n = 15); open circle, OmniMFA-HDR (n = 127); light-grey closed circle, adherent-OmniMFA-VDR (n = 10);
dark-grey closed circle, nonadherent-OmniMFA-VDR (n = 21); open triangle, OmniProt-HDR (n = 113); light-grey closed triangle, adherent-OmniProt-
VDR (n = 10); dark-grey closed triangle, nonadherent-OmniProt-VDR (n = 35). Error bars indicate 95% CIs. Missing data include LDL cholesterol (n = 2
for OmniMFA-VDR, OmniProt-VDR, OmniMFA-HDR, OmniProt-HDR and n = 3 for OmniCarb-HDR), HDL cholesterol (n = 1 for OmniMFA-VDR and
OmniProt-VDR), triglycerides (n = 1 for OmniMFA-VDR and OmniProt-VDR), and total cholesterol (n = 1 for OmniMFA-VDR and OmniProt-VDR).
Signiicant t test comparison between baseline and post-OmniHeart diets: *P< 0.05; †P< 10−5; ‡P< 10−10. DBP, diastolic blood pressure; HDR, homogeneous
dietary response; OmniCarb, OmniHeart carbohydrate-rich diet; OmniHeart, Optimal Macronutrient Intake Trial for Heart Health; OmniMFA, OmniHeart
monounsaturated fat–rich diet; OmniProt, OmniHeart protein-rich diet; VDR, variable dietary response.
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TABLE 3
Stratiication by urinary phenotypes1
Summary of sub-phenotypes N %
Group 1: HDR to all 3 diets 95 60.1
Group 2: HDR to 2 diets but VDR to 1 diet 35 22.2
(a) Nonadherent-VDR to the other diet 25 15.8
(b) Adherent-VDR to the other diet 10 6.3
Group 3: HDR to 1 diet but VDR to 2 diets 22 13.9
(a) Nonadherent-VDR to the other 2 diets 11 7.0
(b) Adherent-VDR to the other 2 diets 2 1.2
(c) Mixed response—nonadherence-VDR to 1 diet and adherent-VDR to the other diet 9 5.7
Group 4: Nonadherent-VDR to all 3 diets 4 2.5
Group 5: Mix of nonadherent and adherent to all 3 diets 2 1.3
1Individuals were stratiied based on diet-speciic urinary phenotypes. HDR, homogeneous dietary response; VDR,
variable dietary response.
have manipulated gut microbiota balance via probiotic admin-
istration with consequent beneicial effects on BP levels (37).
More recently, blood concentrations of phenylacetylglutamine
were found to be strongly anti-correlated with BP, consistent with
our results, and with carotid-femoral pulse-wave velocity, a mea-
sure of aortic stiffness (38). Although 4-cresyl sulfate has never
been formally linked to BP, its dietary excretion has been shown
to be highly correlated with that of phenylacetylglutamine (16).
The association between gut-microbial co-metabolites and BP
is further evidenced in the direct association we found between
BP and hippurate, originating from the conversion of benzoic acid
by gut microlora via the shikimate pathway (39). In contrast to
our results, hypertensive rats showed an anti-correlation between
hippurate and BP (40) but interpolation from animal data to hu-
man must be performed with care due to the differences in gut
microbiomes between species. An inverse association between
excretion of hippurate and BP has been reported in humans but
this association was not signiicant after adjusting for BMI, alco-
hol intake, and urinary excretion of sodium and potassium (41).
A controlled feeding study byWu et al. (35) showed that changes
in the gut microbiome occurred within 24 h of initiating a change
in diet and that BMI and weight loss can also inluence the gut
microbiome composition. However, in our dietary intervention
study, all participants consumed a consistent healthy dietary pat-
tern for 6 wk and maintained their body weight, with micronu-
trients being indexed to the energy level of their diets. Our data,
therefore, suggest modulation of diets can affect gut microbiome
activity and that this may lead to a direct effect on BP regulation.
We observed an inverse association of N-methyl-2-
pyridone-5-carboxamide (tryptophan–NAD metabolite)
and BP. Bartus et al. (42) showed that ingestion of
1-methylnicotinamide in hypertriglyceridemic rats resulted
in an increase of 1-methylnicotinamide and its metabo-
lites such as N-methyl-2-pyridone-5-carboxamide and found
that ingestion of 1-methylnicotinamide in both the dia-
betic and hypertriglyceridemic rats can ameliorate the ni-
tric oxide-dependent vasodilation, a surrogate marker for
atherosclerosis. Others have found that 1-methylnicotinamide
demonstrates anti-thrombotic activity (43). Our indings fur-
ther support the beneicial impact of N-methyl-2-pyridone-5-
carboxamide on CVD health. We suggest the tryptophan–NAD
pathway may offer a new target for pharmacological treatment
of hypertension.
We also conirmed the association of dietary markers with
BP including: a direct association between BP and carnitine (a
marker for protein ingestion); and an inverse association with
proline-betaine (citrus fruit ingestion). Our results are consistent
with previous studies linking hypertension with blood concen-
tration of carnitine (44) and variations in BP following carnitine
treatment in rats (45). Similarly our results support the previously
postulated beneit of citrus fruit intake in reduction of BP (34).
Speciically for the OmniProt diet, despite the increased excre-
tion of carnitine, a marker which was linked to higher BP, over-
all beneicial reductions in CVD risk factors (both BP levels and
lipid proiles) were elicited and these beneits persisted for those
who were considered as typical (HDR) as well as variable (VDR)
responders. The speciic mechanisms for this remain unclear al-
though it may be hypothesized that the altered large-bowel mi-
crobiome following protein-rich dietary intervention may play a
signiicant role.
We investigated our data stratiied by responders (HDR
groups) and nonresponders (VDR groups) to ascertain whether
the lack of demonstrated response was purely due to poor adher-
ence to diet. We used a marker of citrus fruits, proline-betaine, as
a proxy for dietary adherence to OmniHeart diets, as participants
were given citrus fruits as part of their diets. Using the level of
proline-betaine excretion at<95%CI of the HDR groups as a cut-
off, we estimated that nonadherence contributed to the dampened
clinical responses for 9.5–22.2% of the participants, depending
on the type of OmniHeart diet. These nonadherence values are
considerably higher than the <5% nonadherence estimated from
the self-reported data from this study (4) and provided an addi-
tional objective measure to the mean urine urea nitrogen mea-
surements, relecting protein intake, which was highest on the
protein-rich diet. Our modeling strategy thus provided an objec-
tive method for classiication of individuals in the VDR groups as
nonadherent to each of the OmniHeart diets. The remaining dis-
crepancy in metabolic response in individuals showing good
dietary adherence was mainly attributable to variation in the ex-
cretion of gut microbial metabolites (7.6%). These results are
consistent with indings from a recent study by Zeevi et al. (46)
who showed interindividual differences in glycemic response to
foods and that these were correlated with differences in the com-
position of the microbiome.
As a feeding study, this study has several strengths including:
the provision of all meals to participants where their bodyweights
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were held constant throughout the feeding periods, thereby re-
moving the confounding effect of weight loss; the inclusion of
24-h urine collection; and the randomized cross-over design,
which all add rigor to the study. Further, we have included in-
dividuals from high CVD risk groups such as African American
(∼50%) and prehypertensive patients (∼80%), which strength-
ens the general applicability of our stratiication pipeline, al-
though we recognize a large proportion of our participants was
either overweight or obese and therefore not relective of the
general population. However, this relects the higher incidence
of obesity among the African American population. Since, by
design, participants’ weight remained the same throughout the
study, our models were not adjusted for BMI. We also did not
adjust for socioeconomic status based on previous indings in
a large-scale cross-sectional study, which demonstrated that the
inverse association with BP was explained mostly by dietary
differences (47).
Our study represents one of the largest dietary interventions
of its kind where many prior nutritional metabolic phenotyping
studies have typically involved a small number of participants
(N < 25) (48, 49). In this study, we used food-frequency ques-
tionnaires to describe participants’ food intake during the screen-
ing visit (baseline) and this information was used to estimate the
average intended food intake to maintain the participants’ body
weight throughout the isocaloric feeding periods. However, one
limitation is that we were unable to perform more detailed anal-
ysis on individual dietary components and the dose–response re-
lation with BP. An additional limitation of the current study was
the use of NMR spectroscopy as the sole method of metabolic
proiling. Although the robustness of the technique is advanta-
geous for generating high-quality data, mass spectrometry would
offer better sensitivity and selectivity andmay have identiied fur-
ther candidate biomarkers relating to BP. Nonetheless, we were
able to uncover a number of biomarkers related to BP and these
biomarkers were structurally authenticated.
In this global proiling study, we opted to use urine as our
choice of bioluid as urine constitutes a rich source of informa-
tion encompassing the inluence of dietary and gut microbiota.
We and others (41, 50) have successfully identiied urinary dis-
criminatory metabolites related to BP. However, future studies
should validate our indings by the use of urine specimens col-
lected from independent epidemiological studies. Further to val-
idating the candidate biomarkers related to dietary modulation
of BP, a series of in vivo studies to establish causality would be
necessary. For example, Menni et al. (51) have shown a possible
causal relation between hexadecanedioate and BP using rodent
models.
Our strategy illustrates the feasibility of adopting a rational
stratiication approach for diabetologists, cardiologists, or dieti-
tians to identify individuals’ nonadherence to diets and to opti-
mize clinical responses to therapy. Extending this concept, we can
envisage that further characterization of interindividual responses
to healthy diets as determined by an individual’s phenotypic pat-
terns and further determining an individual’s longitudinal pheno-
typic stability prior to a healthy dietary intervention would need
to be developed for the identiication of latent sub-phenotypes.
This may confer a public health beneit with potential to provide
a personalized approach to dietary recommendations aimed at
optimizing prevention of CVD and related disorders.
In conclusion, variation in metabolic phenotypes in response
to speciic healthy diets may hold clues as to the mechanisms
underlying interindividual variations in response to dietary mod-
ulation and points to the potential importance of the gut micro-
biome in accounting for differences in dietary response and the
subsequent impact on BP. The worklow presented here provides
a clinically actionable framework to develop tailored dietary in-
terventions designed to reduce BP and other CVD risk factors.
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